Trillium Therapeutics Inc (TRIL)

[Inoviorulez]

I see what you are saying Vinmantoo Tuesday (yesterday) was 10th day for TRIL. There is no risk of delisting.

As for the cash point. They had roughly $38 million cash on hand and projected to last until early 2021. This was before the warrants. Warrants were exercised likely at .95 and then probably on the run up. With warrants being exercised (offered at .95) plus the prior cash, they got plenty of cash to carry the company until 1st half of 2021.

Secondly, it is being handled for anyone that even bothered to look at the presentation. Look at the last slide

"out license STING 1st half of 2020"

This is a hint they are in talks t partner that out for upfront cash and milestone payments. Obviously that is never a guarantee, but they likely have some interested parties. Especially, as you may or may not know this is a second generation STING product and doesn't have a CDN scaffold. CDN scaffold in first generation caused major side effects and couldn't use higher doses. This one from TRIL should be able to. Also it showed anti-tumor activity in preclinical studies both as an oral agent and intravenous agent. tHat flexibility plus being second generation STING leads me to believe it will be outlicensed 1st half 2020 as the company claims.

Last slide towards the end. https://ir.trilliumtherapeutics.com/investors/default.aspx